Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice

Touyz, 2004, Reactive oxygen species and angiotensin II signaling in vascular cells—implications in cardiovascular disease, Braz J Med Biol Res, 37, 1263, 10.1590/S0100-879X2004000800018

Cai, 2003, The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases, Trends Pharmacol Sci, 24, 471, 10.1016/S0165-6147(03)00233-5

Suzuki, 2003, Inflammation and angiotensin II, Int J Biochem Cell Biol, 35, 881, 10.1016/S1357-2725(02)00271-6

Ruiz-Ortega, 2001, Role of the renin–angiotensin system in vascular diseases: expanding the field, Hypertension, 38, 1382, 10.1161/hy1201.100589

Strawn, 2000, Inhibition of early atherogenesis by Losartan in monkeys with diet-induced hypercholesterolemia, Circulation, 101, 1586, 10.1161/01.CIR.101.13.1586

Ferrario, 2002, Use of angiotensin II receptor blockers in animal models of atherosclerosis, Am J Hypertens, 15, S9, 10.1016/S0895-7061(01)02274-9

Halkin, 2002, Potential indications for angiotensin-converting enzyme inhibitors in atherosclerotic vascular disease, Am J Med, 112, 126, 10.1016/S0002-9343(01)01001-4

Yusuf, 2000, Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients, N Engl J Med, 342, 145, 10.1056/NEJM200001203420301

Dahlof, 2002, Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol, Lancet, 359, 995, 10.1016/S0140-6736(02)08089-3

Hannan, 2004, Differential regulation by AT(1) and AT(2) receptors of angiotensin II-stimulated cyclic GMP production in rat uterine artery and aorta, Br J Pharmacol, 141, 1024, 10.1038/sj.bjp.0705694

Santos, 2000, Angiotensin-(1–7): an update, Regul Pept, 91, 45, 10.1016/S0167-0115(00)00138-5

Carey, 2003, Newly recognized components of the rennin–angiotensin system: potential roles in cardiovascular and renal regulation, Endocr Rev, 24, 261, 10.1210/er.2003-0001

Walters, 2005, Angiotensin-(1–7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats, Hypertension, 45, 960, 10.1161/01.HYP.0000160325.59323.b8

Santos, 2003, Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas, Proc Natl Acad Sci USA, 100, 8258, 10.1073/pnas.1432869100

Albiston, 2001, Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase, J Biol Chem, 276, 48623, 10.1074/jbc.C100512200

Miller-Wing, 1993, Central angiotensin IV binding sites: distribution and specificity in guinea pig brain, J Pharmacol Exp Ther, 266, 1718

Swanson, 1992, Discovery of a distinct binding site for angiotensin II (3–8), a putative angiotensin for a receptor, Regul Pept, 40, 409, 10.1016/0167-0115(92)90527-2

Kerins, 1995, Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV, J Clin Invest, 96, 2515, 10.1172/JCI118312

Patel, 1998, Angiotensin IV receptor-mediated activation of lung endothelial NOS is associated with vasorelaxation, Am J Physiol, 275, L1061

Albiston, 2003, AT4 receptor is insulin-regulated membrane aminopeptidase: potential mechanisms of memory enhancement, Trends Endocrinol Metab, 14, 72, 10.1016/S1043-2760(02)00037-1

Chen, 2000, Angiotensin IV-mediated pulmonary artery vasorelaxation is due to endothelial intracellular calcium release, Am J Physiol Lung Cell Mol Physiol, 279, L849, 10.1152/ajplung.2000.279.5.L849

Kramar, 1997, Angiotensin II- and IV-induced changes in cerebral blood flow. Roles of AT1, AT2, and AT4 receptor subtypes, Regul Pept, 68, 131, 10.1016/S0167-0115(96)02116-7

Hill-Kapturczak, 1999, Angiotensin II-stimulated nitric oxide release from porcine pulmonary endothelium is mediated by angiotensin IV, J Am Soc Nephrol, 10, 481, 10.1681/ASN.V103481

Moeller, 1999, Up regulation of AT4 receptor levels in carotid arteries following balloon injury, Regul Pept, 83, 25, 10.1016/S0167-0115(99)00047-6

Jiang, 2001, Endothelial dysfunction induced by oxidized low-density lipoproteins in isolated mouse aorta: a comparison with apolipoprotein-E deficient mice, Eur J Pharmacol, 424, 141, 10.1016/S0014-2999(01)01140-2

d'Uscio, 2001, Mechanism of endothelial dysfunction in apolipoprotein E-deficient mice, Arterioscler Thromb Vasc Biol, 21, 1017, 10.1161/01.ATV.21.6.1017

d'Uscio, 2001, Hypercholesterolemia impairs endothelium-dependent relaxations in common carotid arteries of apolipoprotein e-deficient mice, Stroke, 32, 2658, 10.1161/hs1101.097393

Shibasaki, 1999, Differential kinetics of circulating angiotensin IV and II after treatment with angiotensin II type 1 receptor antagonist and their plasma levels in patients with chronic renal failure, Clin Nephrol, 51, 83

Daugherty, 2004, Angiotensin II-mediated development of vascular diseases, Trends Cardiovasc Med, 14, 117, 10.1016/j.tcm.2004.01.002

Jones, 2004, Angiotensin AT2 receptor contributes to cardiovascular remodelling of aged rats during chronic AT1 receptor blockade, J Mol Cell Cardiol, 37, 1023, 10.1016/j.yjmcc.2004.08.004

Daugherty, 2004, Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor, Circulation, 110, 3849, 10.1161/01.CIR.0000150540.54220.C4

Faure, 2006, Cerebroprotective effect of angiotensin IV in experimental ischemic stroke in the rat mediated by AT(4) receptors, J Physiol Pharmacol, 57, 329

Griendling, 2000, NAD(P)H oxidase: role in cardiovascular biology and disease, Circ Res, 86, 494, 10.1161/01.RES.86.5.494

Cifuentes, 2000, Upregulation of p67phox and gp91phox in aortas from angiotensin II-infused mice, Am J Physiol Heart Circ Physiol, 279, H2234, 10.1152/ajpheart.2000.279.5.H2234

Moreno, 2002, Changes in NOS activity and protein expression during acute and prolonged ANG II administration, Am J Physiol Regul Integr Comp Physiol, 282, R31, 10.1152/ajpregu.2002.282.1.R31

Yayama, 2006, Angiotensin II stimulates endothelial NO synthase phosphorylation in thoracic aorta of mice with abdominal aortic banding via type 2 receptor, Hypertension, 48, 958, 10.1161/01.HYP.0000244108.30909.27

Mollnau, 2002, Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling, Circ Res, 90, E58, 10.1161/01.RES.0000012569.55432.02

Oak, 2007, Attenuation of angiotensin II signaling recouples eNOS and inhibits nonendothelial NOX activity in diabetic mice, Diabetes, 56, 118, 10.2337/db06-0288

Daugherty, 2000, Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice, J Clin Invest, 105, 1605, 10.1172/JCI7818

Yang, 2006, Recent advances in understanding endothelial dysfunction in atherosclerosis, Clin Med Res, 4, 53, 10.3121/cmr.4.1.53

Rueckschloss, 2002, Dose-dependent regulation of NAD(P)H oxidase expression by angiotensin II in human endothelial cells: protective effect of angiotensin II type 1 receptor blockade in patients with coronary artery disease, Arterioscler Thromb Vasc Biol, 22, 1845, 10.1161/01.ATV.0000035392.38687.65

Ghiadoni, 2003, Different effect of antihypertensive drugs on conduit artery endothelial function, Hypertension, 41, 1281, 10.1161/01.HYP.0000070956.57418.22

Park, 2000, Reduction of resistance artery stiffness by treatment with the AT(1)-receptor antagonist losartan in essential hypertension, J Renin Angiotensin Aldosterone Syst, 1, 40, 10.3317/jraas.2000.009

Schiffrin, 2002, Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function, J Hypertens, 20, 71, 10.1097/00004872-200201000-00011

von zur Muhlen, 2001, Treatment with irbesartan or atenolol improves endothelial function in essential hypertension, J Hypertens, 19, 1813, 10.1097/00004872-200110000-00015

Esteban, 2005, Angiotensin IV activates the nuclear transcription factor-kappaB and related proinflammatory genes in vascular smooth muscle cells, Circ Res, 96, 965, 10.1161/01.RES.0000166326.91395.74

Zulli, 2006, Immunolocalization of ACE2 and AT2 receptors in rabbit atherosclerotic plaques, J Histochem Cytochem, 54, 147, 10.1369/jhc.5C6782.2005

Wright, 1997, Important role for angiotensin III and IV in the brain renin-angiotensin system, Brain Res Brain Res Rev, 25, 96, 10.1016/S0165-0173(97)00019-2

Chai, 2000, Distribution of angiotensin IV binding sites (AT4 receptor) in the human forebrain, midbrain and pons as visualised by in vitro receptor autoradiography, J Chem Neuroanat, 20, 339, 10.1016/S0891-0618(00)00112-5

Loufrani, 1999, Functional evidence for an angiotensin IV receptor in rat resistance arteries, J Pharmacol Exp Ther, 291, 583

Nossaman, 1995, Analysis of responses to ANG IV: effects of PD-123319 and DuP-753 in the pulmonary circulation of the rat, Am J Physiol Lung Cell Mol Physiol, 268, L302, 10.1152/ajplung.1995.268.2.L302